Recently, a group of selective small molecule inhibitors targeting the DNA-binding domain of STAT3 has been identified and shown to inhibit cell proliferation and migration in vitro and tumor development in vivo [25, 26]. This evidence concerns the gene STAT3 and neoplasm.